BTTX
Better Therapeutics, Inc. [BTTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BTTX Stock Summary
In the News
BTTX Financial details
Company Rating
-
Market Cap
648.74K
Income
-31.57M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-0.28
Forward P/E
-
PEG
0.09
P/S
-
P/B
-0.89
P/C
-
P/FCF
-0.42
Quick Ratio
0.51
Current Ratio
0.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
-1.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-294%
ROE
401%
ROC
13.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.005-1.55
52W High
-
52W Low
-
RSI
42.99
Rel Volume
-
Avg Volume
6.13M
Volume
Perf Week
-50%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
100%
-
-
-
-
Beta
2.131
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0002
Change
0%
Company Profile
- Volume Average 6.13M
- Market Capitalization 648.74K
- Employee 54
- CEO Mr. Frank L. Karbe
- Headquarters San Francisco,CA,US
- IPO Date 2021-03-17
-
Website
https://www.bettertx.com 
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
